


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-33. (Canceled).

34. (Currently amended) A compound having [[a]]the name of *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine and a formula of:



(I),

or a pharmaceutically acceptable salt thereof; wherein the compound is stereochemically pure.

35. (Cancelled).

36. (Previously presented) A pharmaceutical composition comprising the compound of claim 34 and at least one pharmaceutically acceptable carrier, filler or diluent.

37. (Previously presented) The pharmaceutical composition of claim 36, wherein the compound is present in an enantiomeric excess of at least 90%.

38. (Previously presented) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, a depression, Schizopreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.

39. (Previously presented) The method of claim 38, wherein the disease or disorder is schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder or mania in bipolar disorder.
40. (Previously presented) The method of claim 39, wherein the schizophrenia comprises positive symptoms.
41. (Previously presented) The method of claim 39, wherein the schizophrenia comprises negative symptoms.
42. (Previously presented) The method of claim 39, wherein the schizophrenia comprises depressive symptoms.
43. (Previously presented) The method of claim 38, wherein the subject is treated with at least one other medicament.
44. (Previously presented) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein: the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, a depression, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder; and the compound is present in an enantiomeric excess of at least 90%.

45-51. (Cancelled).